30-Year Treasury Yield Rises to 4.099% This Week — Data Talk
The 30-year yield rose 0.029 percentage point to 4.099% this week. The price fell 16/32 to 102 18/32.
--Yield is up for two consecutive weeks
--Yield is up 0.123 percentage point over the last two weeks
--Largest two-week yield gain since the week ending June 28, 2024
--Today it is down 0.023 percentage point and the price rose 13/32 price points
--Largest one-day yield decline since Monday, Sept. 16, 2024
--Yield is down for two consecutive trading days
--Yield is down 0.035 percentage point over the last two trading days
--Largest two-day yield decline since Monday, Sept. 16, 2024
--Yield is off 1.002 percentage points from its 52-week high of 5.101% hit Thursday, Oct. 19, 2023
--Yield is up 0.163 percentage point from its 52-week low of 3.936% hit Monday, Sept. 16, 2024
--Yield is down 0.610 percentage point from 52 weeks ago
--Yield is off 0.720 percentage point from its 2024 closing high of 4.819
% hit Thursday, April 25, 2024
--Month-to-date the yield is down 0.097 percentage point
--Year-to-date the yield is up 0.079 percentage point
Data based on 3 p.m. ET values
Source: Tradeweb FTSE U.S. Treasury Closing Prices
(END) Dow Jones Newswires
September 27, 2024 15:48 ET (19:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks